Hepion Pharmaceuticals Inc Stock Price, News & Analysis

On April 17, 2023, Hepion Pharmaceuticals (NASDAQ:HEPA) announced that an abstract regarding its lead drug candidate, rencofilstat, will be presented by Chief Scientific Officer Daren Ure, PhD, at the American Association for Cancer Research Annual Meeting in Orlando, Florida, from April 15-19, 2023. The presentation, titled Rencofilstat Exerts a Dominant Role in Synergistic Anti-PD1-Combination Effects in a Fatty Liver Model of Hepatocellular Carcinoma, is scheduled for April 18, 2023, from 9:00 AM to 12:30 PM ET. Rencofilstat is currently in Phase 2 clinical trials for treating non-alcoholic steatohepatitis (NASH) and has received Fast Track and Orphan Drug designations from the FDA for its potential applications. The company utilizes its proprietary AI platform, AI-POWR™, for precision medicine in identifying responsive NASH patients.

Hepion Pharmaceuticals (NASDAQ:HEPA) has appointed four renowned experts to its Scientific Advisory Board (SAB) as of March 30, 2023. This move enhances the company’s expertise in liver disease research and drug development. The new members are Dr. Rohit Loomba, Dr. Vlad Ratziu, Dr. Yury V. Popov, and Dr. Nikolai Naoumov, each bringing extensive backgrounds in hepatology.

Their experience will support Hepion's clinical programs for rencofilstat, aimed at treating NASH and HCC. Rencofilstat is currently in Phase 2 trials, with FDA Fast Track and Orphan Drug designations. Hepion also employs an AI platform, AI-POWR™, to optimize patient outcomes in its drug development.

Hepion Pharmaceuticals (NASDAQ:HEPA) announced that CEO Robert Foster and SVP Patrick Mayo will present in the free webinar "How Artificial Intelligence is Changing Drug Discovery" on March 23, 2023, at 1:00 PM ET. They will showcase their AI-POWR™ platform, which enhances drug target selection and clinical study design for fibrotic diseases like NASH and HCC. The AI-POWR™ platform integrates extensive clinical data with publicly available multi-omic databases, identifying biomarkers for patient response to rencofilstat, Hepion's lead drug. This innovative approach aims to optimize ongoing clinical trials and improve patient outcomes in drug development.

Hepion Pharmaceuticals (NASDAQ:HEPA) announced that Chief Medical Officer Todd Hobbs will present an update on the NASH clinical program for rencofilstat at the Global NASH Congress on March 3, 2023. The presentation will cover the ASCEND-NASH and ALTITUDE-NASH trials, focusing on timelines and progress. The ASCEND-NASH trial, involving 90 sites across North America and Europe, aims for complete enrollment within 12 months. The ALTITUDE-NASH trial reached full enrollment in December 2022, with topline results expected in Q2 2023. The FDA has granted Fast Track and Orphan Drug designations for rencofilstat, highlighting its potential for treating NASH and HCC.

Hepion Pharmaceuticals has announced the granting of European Patent No. EP 3886813 for its lead drug candidate, rencofilstat, covering 38 European countries. This patent extends the exclusivity period to potentially 2048, providing a crucial competitive advantage. This extension builds on Hepion’s existing patent portfolio, originally set to expire in 2036. Rencofilstat, which inhibits cyclophilins and targets conditions like NASH and HCC, is in Phase 2 clinical trials and benefits from both FDA Fast Track and Orphan Drug designations.

CEO Robert Foster emphasized the importance of this patent for protecting rencofilstat's market potential amidst growing interest from researchers.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced that CEO Robert Foster will ring the Nasdaq Closing Bell on February 10, 2023. The event highlights the company’s focus on AI-driven therapeutic development for conditions like NASH and hepatocellular carcinoma. Rencofilstat, its lead drug candidate, has shown efficacy in reducing liver fibrosis and tumor burden and is currently in Phase 2 clinical development for NASH. The FDA has granted it both Fast Track and Orphan Drug designations. Hepion also introduced its AI-POWR™ platform, aimed at improving patient outcomes in clinical trials and exploring new therapeutic indications.

Hepion Pharmaceuticals (NASDAQ:HEPA) announced encouraging results from preclinical studies on rencofilstat for multiple myeloma (MM). The drug showed complete cytotoxicity across 16 MM cell lines, including bortezomib-resistant types, when combined with bortezomib. Rencofilstat's effects correlated with reduced expression of targets cyclophilins A and D. The results align with previous studies advocating cyclophilin inhibition for treating resistant MM. CEO Robert Foster highlighted ongoing Phase 2 trials for NASH while exploring rencofilstat's broader therapeutic potential. The FDA has previously granted rencofilstat Fast Track and Orphan Drug designations.

Hepion Pharmaceuticals (NASDAQ:HEPA) announced significant findings from a preclinical study on its lead candidate, rencofilstat, presented by collaborator Dr. Carlos Perez-Stable at the Florida Cancer Symposium. The study explored the combination of rencofilstat with ixazomib, showing that together they induced proteotoxic stress, killing 70-90% of various prostate cancer cell lines without harming non-cancer cells. This suggests potential advancements in cancer treatment applications for rencofilstat, alongside its ongoing Phase 2 trials for non-alcoholic steatohepatitis (NASH).